Back to Search
JOHN WOOLFREY, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1417213711IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
UNIVERSITY OF IOWA, RJ & L CARVER COLLEGE OF MEDICINE
Class of 2012
Research & Publications (15)
The use of computational methods in the discovery and design of kinase inhibitors.
PMID 12052199·Curr Pharm Des·2002
6-review
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
PMID 19297154·Bioorg Med Chem Lett·2009
4-observational
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
PMID 18413839·Clin Cancer Res·2008
8-other
Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.
PMID 15225723·Bioorg Med Chem Lett·2004
8-other
N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.
PMID 15080981·Bioorg Med Chem Lett·2004
8-other
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.
PMID 15013007·Bioorg Med Chem Lett·2004
7-preclinical
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
PMID 14980671·Bioorg Med Chem Lett·2004
7-preclinical
Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitors.
PMID 12639568·Bioorg Med Chem Lett·2003
8-other
Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.
PMID 12565972·Bioorg Med Chem Lett·2003
7-preclinical
Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.
PMID 12039584·Bioorg Med Chem Lett·2002
7-preclinical
Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.
PMID 12039583·Bioorg Med Chem Lett·2002
7-preclinical
Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors.
PMID 12031331·Bioorg Med Chem Lett·2002
4-observational
Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies.
PMID 11784134·J Med Chem·2002
8-other
Design, synthesis, and SAR of amino acid derivatives as factor Xa inhibitors.
PMID 11677132·Bioorg Med Chem Lett·2001
8-other
Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors.
PMID 11527714·Bioorg Med Chem Lett·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 700 LAWRENCE EXPY
SANTA CLARA, CA 95051 - Phone
- (408) 851-1000
Quick Facts
- NPI
- 1417213711
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 14
- Publications
- 15
Are you this provider?
Claim Your Profile